Quantitative and qualitative anamnestic immune responses to pneumococcal conjugate vaccine in HIV-infected and HIV-uninfected children 5 years after vaccination

Journal of Infectious Diseases

Volumn 199, Issue 8, 2009, Pages 1168-1176

  Madhi, Shabir A ^a,d   Klugman, Keith P ^a,b,c   Kuwanda, Locadiah ^a   Cutland, Clare ^a   Käyhty, Helena ^b,c   Adrian, Peter ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b EMORY UNIVERSITY   (United States)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PNEUMOCOCCUS VACCINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIVIRAL THERAPY; ARTICLE; CD4+ T LYMPHOCYTE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME IMMUNOASSAY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MALE; PNEUMOCOCCAL INFECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; SEROTYPE; VACCINATION;

ANTI-HIV AGENTS; ANTIBODIES, BACTERIAL; CHILD, PRESCHOOL; FEMALE; HIV INFECTIONS; HUMANS; IMMUNIZATION SCHEDULE; MALE; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; VACCINATION;

EID: 65649124687     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/597388     Document Type: Article

References (23)

1. Madhi SA, Petersen K, Madhi A, Wasas A, Klugman KP. Impact of human immunodeficiency virus type 1 on the disease spectrum of Streptococcus pneumoniae in South African children. Pediatr Infect Dis J 2000; 19:1141-7.
2. Black S, Shinefield H, Fireman B, et al.Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000; 19:187-95.
3. Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003; 349:1341-8.
4. Cutts FT, Zaman SM, Enwere G, et al.Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebocontrolled trial. Lancet 2005; 365:1139-46.
5. Madhi SA, Adrian P, Kuwanda L, et al.Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine. Vaccine 2007; 25:2451-7.
6. Wyeth. Pneumococcal 7-valent conjugate vaccine (diphtheria CRM197 protein): Prevnar®. Available at: http://www.wyeth.com/content/showlabeling. asp?id-134. Accessed 23 July 2008.
7. Concepcion NF, Frasch CE. Pneumococcal type 22f polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 2001; 8:266-72.
8. Simell B, Lahdenkari M, Reunanen A, Kayhty H, Vakevainen M. Effects of ageing and gender on naturally acquired antibodies to pneumococcal capsular polysaccharides and virulence-associated proteins. Clin Vaccine Immunol 2008; 15:1391-7.
9. Quataert S, Martin D, Anderson P, et al.A multi-laboratory evaluation of an enzyme-linked immunoassay quantitating human antibodies to Streptococcus pneumoniae polysaccharides. Immunol Invest 2001; 30:191-207.
10. Plikaytis BD, Goldblatt D, Frasch CE, et al.An analytical model applied to a multicenter pneumococcal enzyme-linked immunosorbent assay study. J Clin Microbiol 2000; 38:2043-50.
11. Romero-Steiner S, Libutti D, Pais LB, et al.Standardization of an opsonophagocytic assay for the measurement of functional antibody activ- ity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin Diagn Lab Immunol 1997; 4:415-22.
12. Ekstrom N, Vakevainen M, Verho J, Kilpi T, Kayhty H. Functional antibodies elicited by two heptavalent pneumococcal conjugate vaccines in the Finnish Otitis Media Vaccine Trial. Infect Immun 2007; 75:1794-800.
13. Centers for Disease Control and Prevention. 1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. Official authorized agenda: human immunodeficiency virus infection codes and official guidelines for coding and reporting ICD-9-CM. MMWR 1994; 43(RR-12):1-7.
14. Siber GR, Chang I, Baker S, et al.Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine 2007; 25:3816-26.
15. Gona P, Van Dyke RB, Williams PL, et al.Incidence of opportunistic and other infections in HIV-infected children in the HAART era. JAMA 2006; 296:292-300.
16. Heffernan RT, Barrett NL, Gallagher KM, et al.Declining incidence of invasive Streptococcus pneumoniae infections among persons with AIDS in an era of highly active antiretroviral therapy, 1995-2000. J Infect Dis 2005; 191:2038-45.
17. Spoulou VI, Tsoumas DL, Papaevangelou VG, Mostrou GI, Theodoridou MC. Immunogenicity and immunological memory induced by a 7-valent pneumococcal CRM197 conjugate vaccine in symptomatic HIV-1 infected children. Vaccine 2005; 23:5289-93.
18. King JC Jr, Vink PE, Chang I, et al.Antibody titers eight months after three doses of a five-valent pneumococcal conjugate vaccine in HIV and non-HIV-infected children less than two years of age. Vaccine 1998; 16: 361-5.
19. Malaspina A, Moir S, Kottilil S, et al.Deleterious effect of HIV-1 plasma viremia on B cell costimulatory function. J Immunol 2003; 170:5965-72.
20. Abzug MJ, Pelton SI, Song LY, et al.Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virusinfected children receiving highly active antiretroviral therapy. Pediatr Infect Dis J 2006; 25:920-9.
21. Tarrago D, Casal J, Ruiz-Contreras J, et al.Assessment of antibody response elicited by a 7-valent pneumococcal conjugate vaccine in pediatric human immunodeficiency virus infection. Clin Diagn Lab Immunol 2005; 12:165-70.
22. Henckaerts I, Goldblatt D, Ashton L, Poolman J. Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22F inhibition at low antibody concentrations in pediatric sera. Clin Vaccine Immunol 2006; 13:356-60.
23. Madhi SA, Kuwanda L, Cutland C, Holm A, Kayhty H, Klugman KP. Quantitative and qualitative antibody response to pneumococcal conjugate vaccine among African human immunodeficiency virus-infected and uninfected children. Pediatr Infect Dis J 2005; 24:410-6.